1 |
Sachdeva S, Khandait H, Kopel J, Aloysius MM, Desai R, Goyal H. NAFLD and COVID-19: a pooled analysis. SN Compr Clin Med 2020 Nov 6 [Epub]. DOI: https://doi.org/10.1007/s42399-020-00631-3.
DOI
|
2 |
Gao F, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol 2021;36(1):204-207. DOI: https://doi.org/10.1111/jgh.15112.
DOI
|
3 |
World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Geneva: World Health Organization; 2020.
|
4 |
Central Disease Control Headquarters; Central Disaster Management Headquarters. Coronavirus infectious disease-19 response guidelines (for local governments). Sejong: Ministry of Health and Welfare; 2021.
|
5 |
Kim JH. Vaccine supply plan that doesn't fit anything. Hankyoreh [Internet]. 2021 Aug 9 [cited 2021 Aug 15]. Available from: https://www.hani.co.kr/arti/society/health/1007052.html.
|
6 |
Azar KMJ, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff (Millwood) 2020;39(7):1253-1262. DOI: https://doi.org/10.1377/hlthaff.2020.00598.
DOI
|
7 |
Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol 2021;74(3):567-577. DOI: https://doi.org/10.1016/j.jhep.2020.09.024.
DOI
|
8 |
Ministry of Health and Welfare. Coronavirus disease-19, Republic of Korea [Internet]. Sejong: Ministry of Health and Welfare; 2021 [cited 2021 Aug 15]. Available from: http://ncov.mohw.go.kr/.
|
9 |
Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis. J Med Virol 2021;93(1):257-261. DOI: https://doi.org/10.1002/jmv.26237.
DOI
|
10 |
Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol 2013;28 Suppl 4:64-70. DOI: https://doi.org/10.1111/jgh.12271.
DOI
|
11 |
Park S, Choi GJ, Ko H. Information technology-based tracing strategy in response to COVID-19 in South Korea: privacy controversies. JAMA 2020;323(21):2129-2130. DOI: https://doi.org/10.1001/jama.2020.6602.
DOI
|
12 |
Yang Y, Kim H, Hwang J. Quarantine facility for patients with COVID-19 with mild symptoms in Korea: experience from eighteen residential treatment centers. J Korean Med Sci 2020;35(49):e429. DOI: https://doi.org/10.3346/jkms.2020.35.e429.
DOI
|
13 |
Raifman MA, Raifman JR. Disparities in the population at risk of severe illness from COVID-19 by race/ethnicity and income. Am J Prev Med 2020;59(1):137-139. DOI: https://doi.org/10.1016/j.amepre.2020.04.003.
DOI
|
14 |
Ingraham NE, Lotfi-Emran S, Thielen BK, Techar K, Morris RS, Holtan SG, et al. Immunomodulation in COVID-19. Lancet Respir Med 2020;8(6):544-546. DOI: https://doi.org/10.1016/S2213-2600(20)30226-5.
DOI
|
15 |
Im HJ, Ahn YC, Wang JH, Lee MM, Son CG. Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea. Clin Res Hepatol Gastroenterol 2021;45(4):101526. DOI: https://doi.org/10.1016/j.clinre.2020.06.022.
DOI
|
16 |
Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63(8):1500-1515. DOI: https://doi.org/10.1007/s00125-020-05180-x.
DOI
|
17 |
Kanwar P, Kowdley KV. The metabolic syndrome and its influence on nonalcoholic steatohepatitis. Clin Liver Dis 2016;20(2):225-243. DOI: https://doi.org/10.1016/j.cld.2015.10.002.
DOI
|
18 |
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91-95. DOI: https://doi.org/10.1016/j.ijid.2020.03.017.
DOI
|
19 |
Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016;20(2):205-214. DOI: https://doi.org/10.1016/j.cld.2015.10.001.
DOI
|
20 |
Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe COVID-19. Diabetes Metab Syndr 2020;14(5):825-827. DOI: https://doi.org/10.1016/j.dsx.2020.06.013.
DOI
|
21 |
Roca-Fernandez A, Dennis A, Nicolls R, McGonigle J, Kelly M, Banerjee R. High liver fat associates with higher risk of developing symptomatic covid-19 infection-initial UK biobank observations. medRxiv [Preprint] 2020 Jan 1 [Epub]. DOI: https://doi.org/10.1101/2020.06.04.20122457.
DOI
|
22 |
Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999-2014. DOI: https://doi.org/10.1053/j.gastro.2019.11.312.
DOI
|
23 |
Zhou YJ, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol 2020;73(3):719-721. DOI: https://doi.org/10.1016/j.jhep.2020.04.027.
DOI
|
24 |
Bramante C, Tignanelli CJ, Dutta N, Jones E, Tamariz L, Clark JM, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for COVID-19. medRxiv [Preprint] 2020 Sep 2 [Epub]. DOI: https://doi.org/10.1101/2020.09.01.20185850.
DOI
|
25 |
Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67(4):829-846. DOI: https://doi.org/10.1016/j.jhep.2017.05.016.
DOI
|
26 |
Younossi ZM, Stepanova M, Lam B, Cable R, Felix S, Jeffers T, et al. Independent predictors of mortality among patients with NAFLD hospitalized with COVID-19 infection. Hepatol Commun 2021 Jul 21 [Epub]. DOI: https://doi.org/10.1002/hep4.1802.
DOI
|
27 |
Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the patient with obesity: the editors speak out. Obesity (Silver Spring) 2020;28(5):847. DOI: https://doi.org/10.1002/oby.22808.
DOI
|
28 |
Mahamid M, Nseir W, Khoury T, Mahamid B, Nubania A, Sub-Laban K, et al. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. Eur J Gastroenterol Hepatol 2021;33(12):1578-1581. DOI: https://doi.org/10.1097/MEG.0000000000001902.
DOI
|